title: Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.
abstract: Sunitinib is one of the first targeted treatments for metastatic renal cell carcinoma (mRCC) and is currently considered as the standard of care for most of the mRCC patients in the first-line setting. The introduction of targeted treatments has, in the past few years, led to improvements in disease management and survival of these patients, however, with increasing cost. Cost-effectiveness of sunitinib has been assessed on several occasions and a systematic literature search was conducted to find all published research articles as well as all research abstracts presented in various congresses. This article presents an overview of the currently existing cost-effectiveness studies of sunitinib in mRCC, along with the main results and the utilized methodology. In most of the economic evaluations sunitinib has been deemed to be a cost-effective treatment option compared with other treatments.
authors.affiliation: Pharmacoeconomics and Outcomes Research Unit, School of Pharmacy, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland. timo.purmonen@uef.fi
authors.forename: Timo T
authors.initials: TT
authors.lastname: Purmonen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D003362:Cost-Benefit Analysis; D016503:Drug Delivery Systems; D006801:Humans; D007211:Indoles / Q000191:economics* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D009362:Neoplasm Metastasis; D011758:Pyrroles / Q000191:economics* / Q000627:therapeutic use; D000077210:Sunitinib; D013534:Survival
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib